The role of imaging techniques in the management of multiple myeloma
Open Access
- 11 August 2012
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 159 (5) , 499-513
Abstract
Summary: Bone disease is the major feature of multiple myeloma (MM). Imaging is required for correct staging, in the follow‐up after treatment and, as recently highlighted, is predictor of prognosis. In the near future, whole‐body X‐Ray may be replaced by more sensitive techniques, such as whole‐body low‐dose computerized tomography (CT). Magnetic resonance imaging (MRI) is the gold standard method for assessing bone marrow infiltration of the spine, predicting the risk of vertebral fracture and distinguishing between benign and malignant osteoporosis. Positron emission tomography (PET) with CT (PET/CT) provides important information about the extent of whole‐body disease, including soft tissue masses, and is the best tool to distinguish between active or inactive disease after therapy. Both MRI and PET/CT are predictors of clinical outcome. A prospective use of these newer imaging techniques in both clinical trials and clinical practice may help optimize MM management in the near future.Keywords
This publication has 84 references indexed in Scilit:
- Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myelomaHaematologica, 2012
- Advances in Imaging and the Management of Myeloma Bone DiseaseJournal of Clinical Oncology, 2011
- Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Response Assessment Before High-Dose Chemotherapy for Lymphoma: A Systematic Review and Meta-AnalysisThe Oncologist, 2010
- Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myelomaAnnals of Hematology, 2009
- F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myelomaBlood, 2009
- From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid TumorsJournal of Nuclear Medicine, 2009
- Criteria for diagnosis, staging, risk stratification and response assessment of multiple myelomaLeukemia, 2008
- 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myelomaWorld Journal of Surgical Oncology, 2007
- Multiple myelomaCancer Imaging, 2004
- Positron Emission Tomography (PET) for Staging of Solitary PlasmacytomaCancer Biotherapy and Radiopharmaceuticals, 2003